新消息！鸿蒙操作系统市场占有率首次超越iOS，标志着国产操作系统取得重大突破

鸿蒙操作系统市场占有率首次超越iOS，标志着国产操作系统取得重大突破

北京 - 2024年6月18日 - 根据市场研究机构Counterpoint Research发布的最新数据，华为鸿蒙操作系统（HarmonyOS）在中国市场的份额在2024年第一季度达到了17%，首次超越了苹果iOS的16%，成为中国第二大移动操作系统。这一消息标志着国产操作系统在与安卓和iOS的竞争中取得了重大突破。

鸿蒙操作系统自2019年8月首次发布以来，一直致力于打造面向万物互联时代的全场景操作系统。经过多年的研发和积累，鸿蒙操作系统已经逐渐成熟，并开始在智能手机、平板电脑、智能手表等多种设备上搭载。

鸿蒙操作系统能够取得快速增长，得益于以下几个因素：

• 华为手机的强劲销量：华为是全球第三大智能手机厂商，拥有庞大的用户基数。随着华为手机销量的不断增长，鸿蒙操作系统的装机量也随之增加。
• 鸿蒙操作系统的独特优势：鸿蒙操作系统采用了分布式架构，能够实现多设备之间的无缝协作，为用户提供更加便捷、流畅的使用体验。此外，鸿蒙操作系统还具有开放、安全的特点，吸引了众多开发者和合作伙伴的加入。

尽管鸿蒙操作系统取得了令人瞩目的成绩，但其未来发展仍面临着一些挑战。首先，鸿蒙操作系统尚未完全摆脱对安卓的依赖，需要进一步提升自身的原创技术和核心竞争力。其次，鸿蒙操作系统的生态建设仍处于起步阶段，需要吸引更多开发者和用户加入。

总体而言，鸿蒙操作系统已经取得了良好的开局，并有望成为未来操作系统市场的重要竞争力量。随着鸿蒙操作系统的不断完善和发展，其市场份额有望进一步增长。

以下是新闻稿的几点补充:

• 除了智能手机、平板电脑和智能手表之外，鸿蒙操作系统还将陆续应用于智能家居、车载系统等更多领域。
• 华为已经成立了鸿蒙操作系统开源基金会，旨在推动鸿蒙操作系统的开源和共建。
• 多家国内手机厂商已经宣布将搭载鸿蒙操作系统，这将进一步扩大鸿蒙操作系统的市场份额。

我相信，随着鸿蒙操作系统的不懈努力，中国操作系统一定会取得更加辉煌的成就。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.